Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease - Wikidata - awgldk - TriplyDB

Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease

Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease

http://www.wikidata.org/entity/Q28190207

about

Adenosine receptors as therapeutic targets Highlights on the development of A(2A) adenosine receptor agonists and antagonists Mefloquine and psychotomimetics share neurotransmitter receptor and transporter interactions in vitro Anti-malarial activity of a non-piperidine library of next-generation quinoline methanols.Gap junction blockers: a potential approach to attenuate morphine withdrawal symptoms.Mefloquine blockade of Pannexin1 currents: resolution of a conflict.Anti-malaria drug mefloquine induces motor learning deficits in humans Neuronal gap junctions are required for NMDA receptor-mediated excitotoxicity: implications in ischemic stroke.Mefloquine induces dose-related neurological effects in a rat model.Utility of alkylaminoquinolinyl methanols as new antimalarial drugs.Prolonged neuropsychiatric effects following management of chloroquine intoxication with psychotropic polypharmacy.A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer.Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patients Adenosine A(2A) receptors in Parkinson's disease treatment.P2X7 receptors mediate ATP release and amplification of astrocytic intercellular Ca2+ signaling.Novel investigational adenosine A2A receptor antagonists for Parkinson's disease.Effectiveness and tolerability of istradefylline for the treatment of restless legs syndrome: an exploratory study in five female patients.Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists.Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations.A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A(2A) receptor antagonists.Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant.History and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents.Identification and characterization of mefloquine efficacy against JC virus in vitro.Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists.Carbenoxolone and mefloquine suppress tremor in the harmaline mouse model of essential tremor.Caffeine and a selective adenosine A2A receptor antagonist induce reward and sensitization behavior associated with increased phospho-Thr75-DARPP-32 in mice.Modulation of seizures and synaptic plasticity by adenosinergic receptors in an experimental model of temporal lobe epilepsy induced by pilocarpine in rats.

P2860

Q24632095-97E5DDE7-D04B-4DE6-A86D-472BCD2C47EC Q28279556-4F4CD913-659D-42EE-AC54-0E077C6B6AE8 Q28307141-1CE5D643-91EB-4C12-B8E8-A1DA8A232B88 Q33530732-7B3C55AF-C303-4C9F-82D7-3D8D1DDA1FBB Q33586541-CA99CB56-8E75-44AD-9FA5-E7613EE79C6F Q33787904-E70EEC2A-D78F-46FF-A65F-FCB8F531B83E Q34374374-30FC113F-B5E8-4ABD-AA72-9534173C9599 Q34430454-8020CD11-8447-46B5-A06E-A26FD3584CA1 Q34509705-42326096-6E9C-4B41-9370-0716F01751B2 Q35215427-D6A7FE87-3F92-4BD9-8FC8-317A6C2606B9 Q35841781-02685CAA-CE4C-4C8E-B8D4-F1BE0D39482F Q36090771-3D598370-2062-4ECD-A3C1-4D971CFA1103 Q36278433-091008C1-53A3-4028-8333-B86EAF088FCE Q36973390-8CF4D164-870E-45BE-8FD5-B4DA9E789F03 Q36981083-8A470CDB-F3A3-43F8-8E93-9F1390E6B6A1 Q37627259-69047F29-E66E-43D0-8121-F1C218A0F21C Q37672812-603E34C5-B07A-47D1-98BC-2B6035482004 Q37844573-35BA53E9-02A5-4FB1-9255-52D0A501E8C1 Q38103966-C2C30D83-665E-4603-9140-DBA4A35B9EC1 Q38169996-912E9A14-4316-4BEB-9B3F-C49FC9DE51BA Q38199744-C3301DFA-0DF8-43BC-A01E-C995C13A2419 Q38395423-F5AFC9EC-E8EE-4C4E-A637-B5ED24DCCA0F Q39877627-A5A0C63A-F1C3-4D34-A65E-57A5DD705CB4 Q40169268-89E0AB8A-A80A-4571-B207-C74CD510E464 Q41945102-F64D45E7-0417-4935-9C79-48E1AF4E060E Q46147144-2908B349-3E7C-4869-BACF-3C03D7D42FFA Q46574500-D6E4E734-C076-4674-8518-EB1415878D0A

P2860

Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease

http://www.wikidata.org/entity/Q28190207

description

2003 nî lūn-bûn

@nan

2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Discovery of nonxanthine adeno ...... eatment of Parkinson's disease

@ast

Discovery of nonxanthine adeno ...... eatment of Parkinson's disease

@en

Discovery of nonxanthine adeno ...... eatment of Parkinson's disease

@nl

type

label

Discovery of nonxanthine adeno ...... eatment of Parkinson's disease

@ast

Discovery of nonxanthine adeno ...... eatment of Parkinson's disease

@en

Discovery of nonxanthine adeno ...... eatment of Parkinson's disease

@nl

prefLabel

Discovery of nonxanthine adeno ...... eatment of Parkinson's disease

@ast

Discovery of nonxanthine adeno ...... eatment of Parkinson's disease

@en

Discovery of nonxanthine adeno ...... eatment of Parkinson's disease

@nl

P1433

Q28190207-481E6A19-4117-42AE-B357-17DC75718912

P1476

Q28190207-8BBE3BFC-B0AC-49CB-97AE-703F0DB5BC02

P2093

Q28190207-035186B1-AABE-491A-9195-4B54EA1DFFE8

Q28190207-0F5FCB6A-644B-405A-B65C-5701FEA6F324

Q28190207-51EDD884-3E26-4B3B-976C-67FD6C597360

Q28190207-5EF33736-C02C-4CED-97E8-8F4165350C5A

Q28190207-BAA449EB-C4E7-4A1D-8781-4C93405CE178

Q28190207-BD82EB0A-871E-4373-8630-D5E5E73C1BAF

Q28190207-BED30B60-8E15-4070-9A32-BFC9C27B87DF

Q28190207-E96609B9-C668-4225-B9E5-E3330CA523F3

Q28190207-E9D86D41-D7B1-4BEB-A149-088B1DD40E6B

Q28190207-FB6BA379-74E1-4010-BCC9-ABF88C732505

P304

Q28190207-ECB3BB24-8D85-4586-A04F-CB673E4A50D8

P31

Q28190207-BC4F9071-79FF-4DF0-9EB8-C9B297923A1A

P3181

Q28190207-A55F39DE-39CD-425A-A31B-350285D600C1

P356

Q28190207-FC8A9AD2-993D-4850-93F2-75A132CE7BA0

P407

Q28190207-438FD0BC-AFCD-407D-A73C-996C1EFCBB74

P433

Q28190207-27AAEE33-DC20-4004-9BC5-3776C3FA6DB0

P478

Q28190207-F4EC052C-81DC-407C-8B81-855685A55F20

P50

Q28190207-99E8BAD8-82BC-4C58-946A-A19CB77E55FA

P577

Q28190207-B1F44BA2-51D0-403A-85E3-4446D54D7F87

P5875

Q28190207-0B4A586B-5ECC-4EA9-ADDB-EE7A94E5A223

P698

Q28190207-E101B230-808E-44ED-B67E-1BD36EE12076

P921

Q28190207-18073232-F833-4533-81DC-6CF6F3221C50

P3181

P356

01.WNL.0000095581.20961.7D

P1433

P1476

Discovery of nonxanthine adeno ...... eatment of Parkinson's disease

@en

P2093

A Misra

http://www.w3.org/2001/XMLSchema#string

A R Knight

http://www.w3.org/2001/XMLSchema#string

D Revell

http://www.w3.org/2001/XMLSchema#string

I A Cliffe

http://www.w3.org/2001/XMLSchema#string

J Lerpiniere

http://www.w3.org/2001/XMLSchema#string

K Benwell

http://www.w3.org/2001/XMLSchema#string

R J Gillespie

http://www.w3.org/2001/XMLSchema#string

R M Pratt

http://www.w3.org/2001/XMLSchema#string

R Upton

http://www.w3.org/2001/XMLSchema#string

S M Weiss

http://www.w3.org/2001/XMLSchema#string

P304

S101-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4221061

http://www.w3.org/2001/XMLSchema#string

P356

10.1212/01.WNL.0000095581.20961.7D

http://www.w3.org/2001/XMLSchema#string

P407

P433

11 Suppl 6

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P50

Colin T Dourish

P577

2003-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8970101

http://www.w3.org/2001/XMLSchema#string

P698

14663021

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease